SigumirСигумир
A peptide mixture extracted from calf or pig cartilage, described in Russian joint-disease reports.
What the studies found
Comparison in people · 2006
Sigumir: clinical report on a tissue-derived preparation
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
Important limitations
- Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction
Comparison in people · 2012
Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age
- Pain, mouth opening and chewing
- Improvement reportedNo numerical outcome changes or comparison-group counts supplied
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
Study notes · methods, sources and limitations
Participants or model 62 older patients with temporomandibular joint diseases
Design 62 older patients with temporomandibular-joint disease; Sigumir as part of prosthetic, functional and pharmacological care.
Important limitations
- The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired. This is a distinct joint-disease report, not replication of every claim in the earlier institute report.
- Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Adv Gerontol. 2012;25(1):181–186. PMID 22708467 · Journal publication
About Sigumir
Identity / background source ↗
Research background
Sigumir is a cartilage-associated peptide preparation studied for joint symptoms. The brochure repeats its outcome table under Cartalax, leaving product attribution uncertain.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2006
Sigumir: clinical report on a tissue-derived preparation
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.
Study notes and original source
Sigumir: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.
- Population / setting
- 64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-10-02.
Comparison in people · 2012
Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
Study notes and original source
Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age
Named tissue-derived preparation · Journal publication
A. K. Iordanishvili, V. V. Samsonov, L. N. Soldatova, A. A. Polens, G. A. Ryzhak · Adv Gerontol. 2012;25(1):181–186. PMID 22708467
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
Results and tables
Reported findings and study design
62 older patients with temporomandibular-joint disease; Sigumir as part of prosthetic, functional and pharmacological care.
Population or model 62 older patients with temporomandibular joint diseases
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain, mouth opening and chewing | Improvement reported | No numerical outcome changes or comparison-group counts supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 62 older patients with temporomandibular joint diseases
- Source reviewed
- PubMed citation and abstract checked; full paper not reviewed.
Study limitations
- The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired.
- This is a distinct joint-disease report, not replication of every claim in the earlier institute report.
Reviewed 2026-10-02.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗